Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00719966 · ClinicalTrials.gov registry record
Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 109
- Enrollment target
NCT00719966: Completed study, sponsored by Mayo Clinic.
NCT00719966 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 109 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00719966 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 109 participants
- Enrollment target
Study Summary
RATIONALE: Aromatase inhibitor therapy is used in treating postmenopausal women who have hormone-dependent breast cancer. It is not yet known what effect aromatase inhibitor therapy has on blood vessel function. PURPOSE: This clinical trial is studying the effect of aromatase inhibitor therapy on blood vessel function in postmenopausal women with breast cancer.
Interventions
- DRUG letrozole
- DRUG anastrozole
- DRUG exemestane
- PROCEDURE assessment of therapy complications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2008-09-18 |
| Est. Completion | 2020-01-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00719966
The ClinicalTrials.gov registry entry for NCT00719966 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which letrozole is the first listed.
NCT00719966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00719966 about?
NCT00719966 is a clinical study titled "Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer". RATIONALE: Aromatase inhibitor therapy is used in treating postmenopausal women who have hormone-dependent breast cancer. It is not yet known what effect aromatase inhibitor therapy has on blood vessel function. PURPOSE: This clinical trial is studying the effect of aromatase inhibitor therapy on b...
What is the current status of trial NCT00719966?
This trial is currently completed. The enrollment target is 109 participants. The study started on 2008-09-18. Estimated completion is 2020-01-24.
What interventions are being tested in trial NCT00719966?
The interventions under investigation include: letrozole (DRUG), anastrozole (DRUG), exemestane (DRUG), assessment of therapy complications (PROCEDURE).
Who is sponsoring clinical trial NCT00719966?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.